238
Views
19
CrossRef citations to date
0
Altmetric
Letter

Sequential combination of high dose methotrexate and l-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm

, , , , , , , & show all
Pages 1633-1637 | Received 13 Sep 2011, Accepted 08 Jan 2012, Published online: 16 Mar 2012

References

  • Adachi M, Maeda K, Takekawa M, . High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol 1994 47:278–282.
  • Chaperot L, Bendriss N, Manches O, . Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001;97:3210–3217.
  • Jaye DL, Geigerman CM, Herling M, . Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms. Mod Pathol 2006;19:1555–1562.
  • Burg G, Kempf W, Cozzio A, . WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol 2005;32:647–674.
  • Petrella T, Dalac S, Maynadie M, . CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Francais d'Etude des Lymphomes Cutanes (GFELC). Am J Surg Pathol 1999;23: 137–146.
  • Feuillard J, Jacob MC, Valensi F, . Clinical and biologic features of CD4(+) CD56(+) malignancies. Blood 2002;99:1556–1563.
  • Petrella T, Bagot M, Willemze R, . Blastic NK-cell lymphomas (agranular CD4+ CD56+ hematodermic neoplasms): a review. Am J Clin Pathol 2005;123:662–675.
  • Herling M, Jones D. CD4+ /CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol 2007;127:687–700.
  • Kohrt H, Advani R. Extranodal natural killer /T cell lymphoma: current concepts in biology and treatment. Leuk Lymphoma 2009;50: 1773–1784.
  • Reimer P, Rudiger T, Kraemer D, . What is CD4+ CD56+ malignancy and how should it be treated? Bone Marrow Transplant 2003;32:637–646.
  • Yamada O, Ichikawa M, Okamoto T, . Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies. Br J Haematol 2001;113:153–160.
  • Adachi M, Maeda K, Takekawa M, . High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol 1994;47:278–282.
  • Nagatani T, Okazawa H, Kambara T, . Cutaneous monomorphous CD4- and CD56-positive large-cell lymphoma. Dermatology 2000;200:202–208.
  • Petrella T, Comeau MR, Maynadie M, . “Agranular CD4+ CD56+ hematodermic neoplasm” (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002;26:852–862.
  • Bayerl MG, Rakozy CK, Mohamed AN, . Blastic natural killer cell lymphoma/leukemia: a report of seven cases. Am J Clin Pathol 2002;117:41–50.
  • Karube K, Ohshima K, Tsuchiya T, . Non-B, non-T neoplasms with lymphoblast morphology: further clarification and classification. Am J Surg Pathol 2003;27:1366–1374.
  • Bekkenk MW, Jansen PM, Meijer CJ, . CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 2004;15: 1097–1108.
  • Reichard KK, Burks EJ, Foucar MK, . CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol 2005;29:1274–1283.
  • Ng AP, Lade S, Rutherford T, . Primary cutaneous CD4+/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases. Haematologica 2006;91:143–144.
  • Ji H, Wang L, Li D, . CD4/CD56 hematodermic neoplasm: a report of three cases. Int J Dermatol 2009;48:743–748.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.